mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2011-703mrj-388Research ArticleСтатьиArticlesК вопросу о «гастропротективных» свойствах тизанидинаThe gastroprotective properties ofKarateevA BKarateevA Baekarateev@rambler.ru20111712201154№4 (2011)6971Copyright © Karateev A.B., 20112011Karateev A.B.Karateev A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/388

Обсуждается вопрос о «гастропротективных» свойствах тизанидина - мышечного релаксанта центрального действия. Отмечено, что нет убедительных данных, свидетельствующих о способности тизанидина снижать риск развития серьезных осложнений со стороны желудочно-кишечного тракта, возникающих на фоне приема нестероидных противовоспалительных препаратов (НПВП), а также уменьшать потребность (среднюю суточную дозу) в НПВП. Указано, что при воспалительных ревматических заболеваниях миорелаксанты (в том числе тизанидин), вероятно, могут быть полезны в ряде случаев как компонент симптоматической терапии.

The gastroprotective properties of tizanidine, a centrally acting myorelaxant, are discussed. It is noted that there is no strong evidence suggesting the ability of tizanidine to reduce the risk of serious gastrointestinal complications arising from with the use of nonsteroidal anti-inflammatory drugs and to decrease their need (average daily dose). It is stated that in inflammatory rheumatic diseases, myorelaxants (including tizanidine) are likely to be useful as a component of symptomatic therapy in a number of cases.

миорелаксантытизанидиннестероидные противовоспалительные препаратыревматические заболеванияжелудочно-кишечные осложненияmyorelaxantstizanidinenonsteroidal anti-inflammatory drugsgastroduodenal complicationsReferences<div><p>rheumatic diseases</p><p>Beebe F., Barkin R., Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005;12(2):151-71.</p><p>Van Tulder M., Touray T., Furlan A. et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252.</p><p>Berry H., Hutchinson D. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res 1988;16(2):75-82.</p><p>Sirdalud Ternilin Asia-Pacific Study group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasm. Curr Ther Res 1998;59:13-22.</p><p>Pareek A., Chandurkar N., Chandanwale A. et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009;18(12):1836-42.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009;167 с.</p><p>Maeda-Hagiwara M., Watanabe H., Kanaoka R. et al. Reduction of centrally-stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats. Arch Int Pharmacodyn 1985;277:321-7.</p><p>Maeda-Hagiwara M., Watanabe H., Kanaoka R. et al. Influence of clonidine and a new related imidazoline derivative (tizanidine) on rat gastric mucosa. Pharmacology 1986;32:109-13.</p><p>Jain N., Kulkarni S., Singh A. Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci 2002;70(24):2857-69.</p><p>Бадокин В.В. Применение Сирдалуда в ревматологической практике. РМЖ 2005;13(24):1586.</p><p>Toussirot E., Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998;56(2):225-40.</p><p>Gran J., Husby G. Ankylosing spondyli-tis. Current drug treatment. Drugs 1992;44(4):585-603</p><p>Felder M. Drug therapy of ankylosing spondylitis. Schweiz Rundsch Med Prax 1991;80(23):636-8.</p><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010;752 с.</p><p>Karol D., Muzyk A., Preud'homme X. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry 2011;33(1):84:1-2.</p><p>Del Rosario M., Weachter R., Flaker G. Drug-induced QT prolongation and sudden death. Mo Med 2010;107(1):53-8.</p><p>Kaddar N., Vigneault P., Pilote S. et al. Tizanidine (Zanaflex): A Muscle Relaxant That May Prolong the QT Interval by Blocking IKr. J Cardiovasc Pharmacol Ther. 2011 [Epub ahead of print].</p><p>Publow S., Branam D. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. Am J Health</p><p>&lt;http://www.03.ru/section/verte-&gt;br/4040418</p></div><br /><div><p>rheumatic diseases</p><p>Beebe F., Barkin R., Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005;12(2):151-71.</p><p>Van Tulder M., Touray T., Furlan A. et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252.</p><p>Berry H., Hutchinson D. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res 1988;16(2):75-82.</p><p>Sirdalud Ternilin Asia-Pacific Study group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasm. Curr Ther Res 1998;59:13-22.</p><p>Pareek A., Chandurkar N., Chandanwale A. et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009;18(12):1836-42.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009;167 с.</p><p>Maeda-Hagiwara M., Watanabe H., Kanaoka R. et al. Reduction of centrally-stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats. Arch Int Pharmacodyn 1985;277:321-7.</p><p>Maeda-Hagiwara M., Watanabe H., Kanaoka R. et al. Influence of clonidine and a new related imidazoline derivative (tizanidine) on rat gastric mucosa. Pharmacology 1986;32:109-13.</p><p>Jain N., Kulkarni S., Singh A. Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects. Life Sci 2002;70(24):2857-69.</p><p>Бадокин В.В. Применение Сирдалуда в ревматологической практике. РМЖ 2005;13(24):1586.</p><p>Toussirot E., Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998;56(2):225-40.</p><p>Gran J., Husby G. Ankylosing spondyli-tis. Current drug treatment. Drugs 1992;44(4):585-603</p><p>Felder M. Drug therapy of ankylosing spondylitis. Schweiz Rundsch Med Prax 1991;80(23):636-8.</p><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010;752 с.</p><p>Karol D., Muzyk A., Preud'homme X. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry 2011;33(1):84:1-2.</p><p>Del Rosario M., Weachter R., Flaker G. Drug-induced QT prolongation and sudden death. Mo Med 2010;107(1):53-8.</p><p>Kaddar N., Vigneault P., Pilote S. et al. Tizanidine (Zanaflex): A Muscle Relaxant That May Prolong the QT Interval by Blocking IKr. J Cardiovasc Pharmacol Ther. 2011 [Epub ahead of print].</p><p>Publow S., Branam D. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. Am J Health</p><p>&lt;http://www.03.ru/section/verte-&gt;br/4040418</p></div><br />

The authors declare that there are no conflicts of interest present.